DPP4 and Hypoglycemia: Additionally, use of high‐affinity sulfonylureas was associated with a 3.48‐fold (95% CI, 2.67–4.55) increased risk of hypoglycaemia and a 31% (HR, 1.31; 95% CI, 1.22–1.40) increased risk of all‐cause mortality compared to DPP‐4 inhibitors.